Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-5.12 Insider Own16.61% Shs Outstand91.02M Perf Week54.00%
Market Cap10.65B Forward P/E- EPS next Y-5.28 Insider Trans1.12% Shs Float76.50M Perf Month39.35%
Income-442.70M PEG- EPS next Q-1.27 Inst Own96.30% Short Float10.76% Perf Quarter41.15%
Sales66.00M P/S161.41 EPS this Y-38.70% Inst Trans5.96% Short Ratio6.70 Perf Half Y123.70%
Book/sh12.75 P/B9.18 EPS next Y-2.70% ROA-34.40% Target Price109.47 Perf Year54.88%
Cash/sh10.14 P/C11.54 EPS next 5Y46.09% ROE-45.50% 52W Range31.38 - 118.40 Perf YTD212.61%
Dividend- P/FCF- EPS past 5Y-28.70% ROI-39.70% 52W High-1.15% Beta2.99
Dividend %- Quick Ratio8.80 Sales past 5Y-10.60% Gross Margin- 52W Low272.98% ATR6.29
Employees514 Current Ratio8.80 Sales Q/Q82.80% Oper. Margin- RSI (14)76.71 Volatility8.95% 5.14%
OptionableYes Debt/Eq0.13 EPS Q/Q-27.60% Profit Margin- Rel Volume1.70 Prev Close113.80
ShortableYes LT Debt/Eq0.13 EarningsAug 09 AMC Payout- Avg Volume1.23M Price117.04
Recom2.30 SMA2036.84% SMA5041.10% SMA20088.86% Volume2,088,278 Change2.85%
Sep-21-17Reiterated Needham Buy $85 → $125
Sep-15-17Initiated Instinet Reduce
Jun-22-17Resumed Jefferies Buy $102
May-15-17Reiterated Chardan Capital Markets Buy $95 → $110
Mar-30-17Initiated UBS Neutral $55
Feb-09-17Reiterated Needham Buy $98 → $68
Feb-02-17Initiated Ladenburg Thalmann Buy
Dec-19-16Reiterated Chardan Capital Markets Buy $89 → $69
Nov-30-16Reiterated Chardan Capital Markets Buy $73 → $89
Nov-16-16Reiterated Needham Buy $137 → $98
Nov-10-16Resumed Leerink Partners Mkt Perform
Oct-07-16Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-06-16Reiterated Stifel Hold $68 → $36
Oct-06-16Reiterated Needham Buy $152 → $137
Oct-06-16Reiterated FBR & Co. Outperform $180 → $100
Oct-06-16Reiterated Chardan Capital Markets Buy $115 → $77
Oct-06-16Downgrade Leerink Partners Outperform → Mkt Perform
Oct-06-16Downgrade JP Morgan Overweight → Neutral
Aug-02-16Initiated Morgan Stanley Overweight
May-26-16Reiterated Chardan Capital Markets Buy $93 → $115
Sep-25-17 09:57AM  Gene Therapy: A Big Week for Many Names Barrons.com
08:00AM  Alnylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform at 13th Annual Meeting of the Oligonucleotide Therapeutics Society Business Wire
Sep-24-17 07:36AM  Edited Transcript of ALNY earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Sep-23-17 10:34AM  3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? Motley Fool
Sep-22-17 07:30AM  [$$] Alnylam's New Medicine To Enter Pricing Debate The Wall Street Journal
Sep-21-17 04:16PM  Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance Investor's Business Daily
03:19PM  Alnylam Pharmaceuticals: Bet or Fold? Barrons.com
02:37PM  Alnylam Pharmaceuticals CEO: Trial results open up the do... CNBC Videos
11:01AM  Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up Zacks
10:26AM  Company News For Sep 21, 2017 Zacks
09:22AM  Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALNY-US : September 21, 2017 Capital Cube
08:56AM  Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Arbutus Biopharma ACCESSWIRE
06:50AM  Alnylam shares surge 40% on drug results that may herald a new type of medicine MarketWatch
03:00AM  Alnylam Pharmaceuticals Shows Market Leadership With Jump To 98 RS Rating Investor's Business Daily
Sep-20-17 05:45PM  Boosting Fair Value on Alnylam After Drug Trial Morningstar +51.71%
05:05PM  What Happened in the Stock Market Today Motley Fool
04:32PM  Here's Why Arbutus Biopharma Corp. Stock Soared Today Motley Fool
04:07PM  Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks Investor's Business Daily
03:29PM  Alnylam's RNAi drug succeeds in key study, shares soar Reuters
02:01PM  Alnylam Notches a Game-Changing RNAi Win Motley Fool
01:18PM  Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today Motley Fool
01:14PM  Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough InvestorPlace
12:23PM  Arbutus LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program GlobeNewswire
12:14PM  What's Next for Alnylam Pharmaceuticals, Inc.? Motley Fool
11:37AM  After 20 Years, A Drug That Silences Genes Succeeds Forbes
11:36AM  Cheer Alnylam's Drug, Pause on Its Platform Bloomberg
10:48AM  Calamities Couldn't Spoil The Bullish Run Zacks
10:23AM  Hurricanes, Earthquakes and Record-High Markets Zacks
10:16AM  Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers TheStreet.com
08:51AM  Why Alnylam Pharmaceuticals Inc (ALNY) Could Be A Buy Simply Wall St.
07:39AM  UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment MarketWatch
07:25AM  Alnylam's genetic disease drug meets main goal in key study Reuters
07:00AM  Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy GlobeNewswire
07:00AM  Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy Business Wire
Sep-18-17 09:00AM  Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You? Motley Fool
Sep-15-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Sep-14-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Sep-13-17 10:16AM  Biotech Gets More Forgiving, But Riskier Bloomberg
Sep-12-17 08:08AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Sep-08-17 11:34PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc. Business Wire
11:20PM  ETFs with exposure to Alnylam Pharmaceuticals, Inc. : September 9, 2017 Capital Cube
10:38AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) ACCESSWIRE
09:53AM  Alnylam Shares Plunge on Patient Death, Dosing Suspended Zacks
Sep-07-17 08:36PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc. Business Wire -15.68%
05:08PM  What Happened in the Stock Market Today Motley Fool
03:32PM  Breaking Down Barclays' New Bullish Calls On Biotech Benzinga
03:25PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alnylam Pharmaceuticals, Inc. Business Wire
03:23PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY) PR Newswire
02:03PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY PR Newswire
12:30PM  Here's Why Alnylam Pharmaceuticals, Inc. Is Slipping Today Motley Fool
10:45AM  Alnylam halts hemophilia drug trial due to patient death, renewing worries over safety American City Business Journals
09:29AM  Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers TheStreet.com
08:56AM  Alnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017 Capital Cube
08:11AM  Alnylam suspends dosing in bleeding disorder study after patient death Reuters
07:43AM  Alnylam suspends bleeding disorder trial dosing after patient death Reuters
07:33AM  Alnylam Pharmaceuticals' stock plunges after 'fatal' event in hemophilia drug program MarketWatch
07:00AM  Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs Business Wire
Sep-06-17 01:35PM  Why September Will Be A 'Make Or Break' Month For These Biotechs Investor's Business Daily
Sep-05-17 04:00PM  Alnylam to Webcast Presentation at 15th Annual Morgan Stanley Global Healthcare Conference Business Wire
Aug-29-17 05:41PM  The Medicines Co's Inclisiran Positive in Extension Study Zacks
Aug-28-17 08:09AM  Sangamo Therapeutics Initiates Dosing in Hemophilia A Study Zacks
07:00AM  New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials Business Wire
Aug-27-17 07:27AM  3 Biotech Stocks That Could Soar in September Motley Fool
Aug-23-17 05:15PM  Alnylam Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALNY) : August 23, 2017 Capital Cube
Aug-18-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Aug-17-17 07:40AM  Featured Company News - Portola Pharmaceuticals' AndexXa(R) Biologics License Application Resubmission Accepted for Review by US FDA ACCESSWIRE
Aug-16-17 08:05AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Aug-15-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Aug-14-17 07:48PM  Merck CEO resigns from Trump council over Charlottesville Reuters
02:22PM  Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo Motley Fool
08:06AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Aug-12-17 08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Aug-11-17 10:14AM  Alnylam Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALNY-US : August 11, 2017 Capital Cube
08:06AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Aug-10-17 04:31PM  Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss Zacks -5.69%
08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Aug-09-17 10:15PM  After 10 months, Alnylam still can't explain patient trial deaths American City Business Journals
09:22PM  Alnylam reports 2Q loss Associated Press
04:00PM  Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity Business Wire
12:20PM  Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call ACCESSWIRE
08:07AM  See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc. Markit
Aug-08-17 02:19PM  Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View Zacks
02:02PM  Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered Zacks
12:42PM  3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings Zacks
10:30AM  Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected Zacks
08:57AM  Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season Zacks
Aug-01-17 04:00PM  Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results Business Wire
Jul-27-17 08:00AM  Alnylam to Host Fourth Annual RNAi Roundtable Webcast Series Business Wire
Jul-12-17 06:18PM  Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth Zacks
Jul-11-17 04:19PM  Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Hemispherx Biopharma Accesswire
Jul-10-17 05:13PM  Could Alnylam Have An Edge On This Smaller Biotech In Rare Disease? Investor's Business Daily -5.55%
10:13AM  Alnylam Commences Phase III Study for Hemophilia Candidate Zacks
09:32AM  Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or... GlobeNewswire
09:30AM  Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors Business Wire
Jul-07-17 09:11AM  Alnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why Motley Fool
07:30AM  Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors Business Wire
Jul-05-17 04:27PM  Biotechs Gained $1.7 Billion Last Week Can They Keep Going? Investor's Business Daily
Jun-29-17 08:40AM  Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod Zacks
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greene Barry EPresidentSep 21Option Exercise12.3311,844146,042100,428Sep 22 05:05 PM
Greene Barry EPresidentSep 20Option Exercise31.3976,8152,411,223165,399Sep 22 05:05 PM
Greene Barry EPresidentSep 20Sale100.0076,8157,681,50088,584Sep 22 05:05 PM
Vaishnaw AkshayEVP, R&DJun 13Option Exercise19.191,66832,00711,965Jun 15 05:45 PM
Sanofi10% OwnerMay 31Buy71.87297,50121,381,39710,554,134Jun 01 07:41 PM
KEATING LAURIESVP, GC and SecretaryMay 30Buy65.3511,500751,50211,500May 31 05:22 PM
Vaishnaw AkshayEVP, R&DMay 23Option Exercise21.3511,000234,85021,297May 25 06:39 PM
Vaishnaw AkshayEVP, R&DMay 23Sale75.0011,000825,00010,297May 25 06:39 PM
Mason MichaelVP, Finance and TreasurerMay 16Option Exercise14.049,375131,5889,375May 17 06:45 PM
Mason MichaelVP, Finance and TreasurerMay 16Sale70.009,375656,2500May 17 06:45 PM
Vaishnaw AkshaySVP, R&DMay 15Option Exercise28.8743,7501,262,87343,047May 17 06:31 PM
Vaishnaw AkshaySVP, R&DMay 15Sale65.0043,7502,843,75010,297May 17 06:31 PM
SHARP PHILIP ADirectorFeb 01Option Exercise31.2925,000782,250165,795Feb 03 04:32 PM
SHARP PHILIP ADirectorFeb 01Sale39.8025,000995,125140,795Feb 03 04:32 PM
SHARP PHILIP ADirectorJan 25Option Exercise31.3915,000470,850155,795Jan 27 04:10 PM
SHARP PHILIP ADirectorJan 25Sale37.9515,000569,250140,795Jan 27 04:10 PM
SHARP PHILIP ADirectorJan 18Option Exercise15.9115,000238,650155,795Jan 20 04:12 PM
SHARP PHILIP ADirectorJan 18Sale37.8315,000567,456140,795Jan 20 04:12 PM
MARAGANORE JOHNChief Executive OfficerJan 05Option Exercise18.661,34025,004149,710Jan 06 04:22 PM
Vaishnaw AkshayEVP, R&DDec 30Option Exercise19.619,547187,25115,297Jan 04 05:30 PM
MARAGANORE JOHNChief Executive OfficerDec 12Option Exercise22.7530,151685,935171,080Dec 14 04:18 PM
Greene Barry EPresidentDec 01Option Exercise22.7555,6051,265,014120,409Dec 05 04:55 PM
Greene Barry EPresidentDec 01Sale42.9931,8251,368,12888,584Dec 05 04:55 PM
Vaishnaw AkshayEVP, R&D, CMONov 30Option Exercise22.7529,165663,50434,915Dec 02 04:59 PM
Vaishnaw AkshayEVP, R&D, CMONov 30Sale44.9929,1651,311,9985,750Dec 02 04:59 PM
PYOTT DAVID E IDirectorOct 13Buy37.0027,9001,032,32827,900Oct 14 04:22 PM
MARAGANORE JOHNChief Executive OfficerOct 12Option Exercise13.267,54099,994140,929Oct 14 04:17 PM
open in yahoo | open in reuters | open in google